Internal Medicine, Endocrinology, Diabetes, & Metabolism · Flint, MI
NPI
1639284672
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
5040 Villa Linde Pkwy
Flint, MI, 48532
Phone (810) 230-0788
Groups this clinician bills Medicare through
Medicare paid, 2024
$218K
4,359 services
Medicare patients, 2024
738
Average age 70
Drug cost, 2024
$7.1M
10,766 prescriptions
Company payments, 2025
$42K
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jamal Hammoud was code 99214 (office e&m - established), 906 times for 464 patients. In total Jamal Hammoud billed 4,359 services in 26 codes, and Medicare paid $218K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-12-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 906 | 464 | $95.14 | $86K |
| 99231 Hospital E&M - Subsequent | Facility | 683 | 112 | $40.45 | $28K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 524 | 367 | $13.36 | $7,002 |
| 99213 Office E&M - Established | Office | 376 | 274 | $66.73 | $25K |
| 83037 Blood Count | Office | 313 | 240 | $9.52 | $2,980 |
| 95251 Test - Miscellaneous | Office | 304 | 177 | $27.11 | $8,241 |
| 82947 Clinical Chemistry | Office | 296 | 203 | $3.84 | $1,136 |
| 83036 Blood Count | Office | 223 | 197 | $9.35 | $2,085 |
| 99232 Hospital E&M - Subsequent | Facility | 149 | 124 | $62.65 | $9,335 |
| 95250 Test - Miscellaneous | Office | 107 | 93 | $106.59 | $11K |
| 76536 Ultrasound - Nonspecific | Office | 106 | 103 | $78.84 | $8,357 |
| 99204 Office E&M - New | Office | 89 | 89 | $121.02 | $11K |
| 96372 Injection Administration | Office | 61 | 56 | $11.18 | $682 |
| 10005 Other Organ Systems | Office | 44 | 42 | $104.46 | $4,596 |
| 99215 Office E&M - Established | Office | 42 | 42 | $124.63 | $5,235 |
By year: 2022 $244K for 5,182 services; 2023 $226K for 4,722 services; 2024 $218K for 4,359 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83037 Blood Count | 313 | 240 | $9.52 | $2,980 |
| 82947 Clinical Chemistry | 296 | 203 | $3.84 | $1,136 |
| 83036 Blood Count | 223 | 197 | $9.35 | $2,085 |
| 82570 Clinical Chemistry | 12 | 12 | $5.08 | $60.96 |
Medicare prescription drug claims, 2024
In 2024, the drug Jamal Hammoud prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,234 prescriptions and refills. In total Jamal Hammoud wrote 10,766 Medicare prescriptions that cost $7.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,234 | 3,244 | 402 | $16K |
| Trulicity Dulaglutide | 886 | 1,380 | 231 | $1.3M |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 723 | 1,768 | 277 | $155K |
| Ozempic Semaglutide | 681 | 1,213 | 192 | $1.1M |
| Metformin Hcl Generic | 634 | 1,645 | 219 | $6,538 |
| Jardiance Empagliflozin | 621 | 1,295 | 187 | $711K |
| Mounjaro Tirzepatide | 490 | 809 | 125 | $835K |
| Humalog Kwikpen U-100 Insulin Lispro | 357 | 757 | 143 | $134K |
| Glimepiride Generic | 239 | 674 | 92 | $2,155 |
| Novolog Flexpen Insulin Aspart | 237 | 495 | 108 | $84K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 204 | 532 | 101 | $21K |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 170 | 455 | 87 | $18K |
| Pioglitazone Hcl Generic | 163 | 326 | 40 | $2,497 |
| Januvia Sitagliptin Phosphate | 156 | 344 | 46 | $176K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 152 | 378 | 99 | $19K |
Brand drugs: 6,416 claims; generic drugs: 3,249 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jamal Hammoud $42K ($42K in general payments such as food, travel and fees and $171 for research) from 31 companies. The largest payer was Lilly USA, LLC with $33K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 45 | $33K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $3,309 |
| Novo Nordisk Inc NVO | 13 | $2,964 |
| Amgen Inc. AMGN | 30 | $417 |
| Corcept Therapeutics CORT | 17 | $312 |
| Beta Bionics, Inc. BBNX | 18 | $273 |
| Xeris Pharmaceuticals, Inc. | 14 | $223 |
| Eli Lilly and Company LLY | 1 | $171 |
| Abbott Laboratories ABT | 10 | $170 |
| Dexcom, Inc. DXCM | 6 | $125 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.